Tracy Warren

Tracy Warren is a lead investor in Portfolia’s Active Aging Funds I and II. Tracy led the Active Aging Fund’s investments in both Madorra and JoyLux. She serves as general partner of Astarte Ventures, an early stage venture firm focused exclusively on women’s and children’s health and wellbeing. Prior to founding Astarte, Tracy was a general partner of Battelle Ventures and its affiliate fund, Innovation Valley Partners, where she focused on investments in health and life sciences. Tracy has led investments in NuPathe, which completed its IPO in 2010 and was subsequently acquired by Teva Pharmaceuticals for over $140 million. She currently serves as Chairman of BioNano Genomics and on the Board of Micro Interventional Devices.

As an entrepreneur, Ms. Warren co-founded NellOne Therapeutics, a soft-tissue regenerative medicine company based on the NELL1 gene based on work initiated at Oak Ridge National Laboratory by her co-founder, Dr. Cymbeline Culiat. As founding CEO, she leads the company’s efforts with respect to strategy, fundraising, business development and licensing for its equine and human therapies.

Having spent over a decade commercializing technologies from nation’s leading institutions, Tracy serves on the Boards of Children’s Research Institute (CRI) at Children’s National Medical Center (Washington, DC) and Clemson University Research Foundation, and is a member of the Business Advisory Council to the Sheikh Zayed Institute for Pediatric Surgical Innovation. In addition to her investment activities, she also provides early-stage leadership to other businesses, currently serving as an adviser and mentor to life science female entrepreneurs through Springboard Enterprises.